Medical Advocates
Dolutegravir
(Tivicay/S/GSK1349572) |
Last
Update:
September 13, 2016
 Documents
identified with this icon are in Portable Document Format (PDF) and require the
Adobe
Acrobat Reader |
|
|
-
A WEEK-IN-REVIEW FEATURED REPORT
POSTER
HIV resistance to dolutegravir (DTG) simultaneously diminishes viral DNA
integration into host cells and viral replication fitness: implications
for HIV reservoirs
T. Mesplede, P. Quashie M. Oliveira, M. Wainberg
Poster
Abstract
-
POSTER
Secondary resistance mutations in the R263K integrase inhibitor resistance
pathway
T. Mesplède, M.A. Wares, N. Osman, P.K. et ak
Paper
Abstract
-
Dolutegravir is non-inferior to raltegravir and shows durable response
through 96 weeks: results from the SPRING-2 trial
F. Raffi, H. Jaeger, D. Motta, et al
Abstract
-
Once-daily
dolutegravir (DTG; S/GSK1349572) has a renal safety profile comparable to
raltegravir (RAL) and efavirenz in antiretroviral (ART)‑naïve adults: 48
week results from SPRING-2 (ING113086) and SINGLE (ING114467)
L.D. Curtis, S. Min, G. Nichols, et al
-
Dolutegravir (DTG)
is superior to raltegravir (RAL) in ART-experienced, integrase naive
subjects: week 48 results from SAILING (ING111762)
P. Cahn, A.L. Pozniak, H. Mingrone3,et
al
|
|
|
|
|
|
|
|
|
XX International AIDS Conference
Dolutegravir Main Page